Tesamorelin
GHRH Analog — Visceral Fat Reduction
Half-life: ~38 min
Research Profile
Relative research assessments — educational reference only.
Target Receptors
Buying peptides in Bali?
See community-reported Bali price ranges for Tesamorelin and 9 other compounds — clinic menus, WhatsApp quotes and import realities.
Open the Bali Price Index →Critical Research Warning
FDA-approved for HIV-associated lipodystrophy only. May raise IGF-1 levels above normal range in some patients — monitor for acromegaly symptoms.
"A 44-amino acid GHRH analog with a trans-3-hexenoic acid N-terminal modification. FDA-approved for HIV-associated lipodystrophy. The most clinically validated GHRH analog for visceral adipose tissue reduction."
Full Description
Tesamorelin is a synthetic GHRH analog consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid group attached at the N-terminus for increased stability. It was FDA-approved in 2010 (brand: Egrifta) for reduction of excess visceral adipose tissue (VAT) in HIV-positive patients with lipodystrophy. Clinical trials demonstrate significant VAT reduction (~15%), increased IGF-1, and improved lipid profiles. Unlike exogenous GH, tesamorelin preserves pulsatile GH release and avoids supraphysiological GH spikes, resulting in a favorable safety profile with low rates of glucose dysregulation.
Mechanism of Action
Binds pituitary GHRHR, stimulating pulsatile GH release. GH then stimulates hepatic IGF-1 production and activates adipose lipolysis — particularly in visceral adipose depots. Preserves physiological pulsatility vs exogenous GH.
Reported Benefits
- • Clinically proven visceral fat reduction (~15% in Phase 3)
- • Preserves pulsatile GH release with favorable safety profile
- • Improves lipid profiles without significant glucose effects
Potential Side Effects
- • Mild arthralgia and joint discomfort
- • Injection site reactions (erythema, pruritus)
- • Peripheral edema and carpal tunnel symptoms
Frequently Asked Questions
How does Tesamorelin differ from growth hormone itself?▼
Is Tesamorelin used for fat loss in non-HIV populations?▼
For Research Reference Only
Not medical advice. Peptides may be regulated or restricted in your jurisdiction.
References
- 1.Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis. PubMed (2026). Ditta AM, et al.. pubmed.ncbi.nlm.nih.gov/42538058/ ↑
- 2.Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. PubMed (2026). Erlandson KM, et al.. pubmed.ncbi.nlm.nih.gov/42419889/ ↑
- 3.Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. PubMed (2026). Beach R, et al.. pubmed.ncbi.nlm.nih.gov/42139091/ ↑
- 4.Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. PubMed (2026). Badran AS, et al.. pubmed.ncbi.nlm.nih.gov/41545261/ ↑
Where to Source Tesamorelin
4 vendors listed · ranked most → least trusted · not an endorsement
Rankings are community-derived. Always independently verify COAs before any research use. PeptidePlaza is not affiliated with any vendor.
Sell Tesamorelin on PeptidePlaza
Get listed as a verified vendor and reach researchers directly.
Related Research Articles
From the PeptidePlaza research blog.